Clinics and pathology

Disease
Tumour of the sympathetic nervous system: medulloadrenal gland (50%), abdominal (25%), thoracic (15%), cervical or pelvic paraspinal ganglia; metastatic at diagnosis in 60% of cases (lymph nodes, bones and bone marrow, liver, skin). Embryonic origin Neural crest cells. Etiology Unknown; possible excess in neurofibromatosis type I, Wiedemann-Beckwith syndrome, and maternal exposure to phenyl hydantoin; exceptional familial cases. Epidemiology Incidence is 5-10 per million children per yr; 10% of cancers in childhood; half cases by the age of 2 yrs, 90% before 6 yrs. Clinics Presenting signs are according to the localization of the tumoural mass; high catecholamin excretion. Pathology Tumours may exhibit various degrees of differentiation: 1-Neuroblastoma: undifferentiated cells that may be arranged in rosettes surrounding a fibrillar centre; 2-Ganglioneuroblastoma: presenting with more fibrillar material and a mixture of the above described with >50% of more mature cells; 3-Ganglioneuroma composed of well differentiated ganglion cells and Schwann cells; a given tumour may contain more and less mature cell areas. Staging (Evans): Stage I: confined to the organ or structure of origin, Stage II: extending beyond the organ, but not crossing the midline (e.g. homolateral lymph nodes may be involved), Stage III: extending and crossing the midline, Stage IV: distant metastases, Stage IVs: stage I or II otherwise in children aged < 1 yr, with metastases in: liver, skin, bone marrow, but not in the bones. Treatment Surgery and/or radiation therapy, and/or chemotherapy. Evolution Spontaneous (and treatment induced) regression or differenciation into benign cells (ganglioneuroma) occurs rarely in tumours (mainly in infant cases). Prognosis Prognosis is very poor in most cases (median survival 1 yr); good outcome (90%) only for patients with lymph nodes negative for tumour (POG stage A); younger patients have better outcome than older patients; cytogenetic and genetic anomalies are of important prognostic value (see below).
Genetics
Note: heterogenous disease from the genetic viewpoint; 90% cases exhibit genetic abnormalities.
Cytogenetics
Morphological cytogenetics
Two types can be delineated according to ploidy: -Aneuploid tumours (near triploid, pentaploid or hexaploid), with whole chromosome anomalies, often with relative gains of chromosomes 17, 7, 6, relative losses of chromosomes 11, 14, X (molecular cytogenetics: detection with comparative genomic hybridization (CGH)); these are low grade tumours, with good prognosis. -Diploid and/or tetraploid tumours, with del(1p) -minimal critical region being 1p36-in 40% cases, del(11q), partial trisomy for 17q21-qter (in 90% of high grade tumours), DM or HSR (N-myc amplification); these anomalies are often associated, found in high grade tumours, and bear a grave prognosis.
Genes involved and Proteins
MYCN
Location: 2p24 Protein Nuclear protein; contains a helix-loop-helix and a leucine zipper; transcription factor.
Result of the chromosomal anomaly
Fusion protein
Oncogenesis Amplification of NMYC is found in various tumours, in particular neuroblastoma; the level of amplification increases with tumour progression.
To be noted
Screening programs in several countries could not induce a fall in mortality
